Immunomodulators Market Growth & Trends
The global immunomodulators market size is expected to reach USD 329.8 million by 2030, expanding at a CAGR of 6.2% from 2024 to 2030. The market is anticipated to be predominantly driven by high R&D investments employed by prominent companies, resulting in the large-scale production of new and therapeutically advanced drugs. This is believed to widen the influx of drugs at an unprecedented rate into the immunomodulators market hence providing highly efficacious treatment alternatives for numerous autoimmune and inflammatory diseases.
In addition, increasing drug resistance is predicted to be responsible for boosting the clinical urgency to develop potentially new generation immunomodulators with targeted therapy mechanisms. The aforementioned factors cumulatively are expected to present significant growth opportunities over the forecast period.
Furthermore, the burgeoning presence of the key players is expected to promote the awareness levels pertaining to the benefits of immunomodulators amongst the patients as well as the physicians. This is further expected to widen the immunomodulators industry growth potential during the forecast period.
In addition, increasing adoption of monoclonal antibodies for a wide range of indications, such as, multiple sclerosis, Crohn’s disease, rheumatoid arthritis, and Non-Hodgkin’s Lymphoma, which is expected to boost immunomodulators industry over the forecast period. The consistent number of product approvals of highly significant monoclonal antibodies in autoimmune diseases is predicted to be responsible for widening the scope of growth.
Immunomodulators Market Report Highlights
- Immunosuppressant held the largest share of the product segment in 2023, owing to the increasing number of transplantation procedures and need to prevent organ rejection
- Antibodies held the dominant share of immunosuppressant in 2023, owing to extensive utilization in kidney, liver, heart, and lung transplants resulting in greater revenue generation
- Immunostimulants expected to grow lucratively as a result of the lower influx of immunostimulant generics for application in HIV, cancer and multiple sclerosis
- In 2023, North America dominated the global immunomodulators market owing to the presence of a wide number of established pharmaceutical companies involved in extensive commercialization
- The prominent participants are undertaking research and clinical collaborative strategies to yield new drugs and thereby to gain competitive advantage
- For instance, In March 2024, Ability Biologics concluded its seed funding, securing a total of USD 18 million in investment. This capital is expected to be directed towards the development of innovative and highly targeted immunomodulators.
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Global Immunomodulators Market Variables, Trends, & Scope
Chapter 4. Global Immunomodulators Market: Product Estimates & Trend Analysis
Chapter 5. Global Immunomodulators Market: Application Estimates & Trend Analysis
Chapter 6. Global Immunomodulators Market: Regional Estimates & Trend Analysis
Chapter 7. Competitive Landscape
Companies Mentioned
- F. Hoffmann-La Roche Ltd
- Amgen Inc.
- Abbott.
- Johnson & Johnson Services, Inc.
- Novartis AG
- Eli Lilly and Company
- Bristol-Myers Squibb Company
- Merck & Co., Inc.
- Biogen
- Pfizer Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 100 |
| Published | August 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 217.5 Million |
| Forecasted Market Value ( USD | $ 329.8 Million |
| Compound Annual Growth Rate | 6.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
